| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Viridian Therapeutics, Inc.\DE | Chief Financial Officer | Restricted Stock Units | 18,801 | $586,842 | $23.41 | 03 Mar 2026 | Direct |
| Viridian Therapeutics, Inc.\DE | Chief Financial Officer | Common Stock | 7,850 | $235,971 | $30.06 | 03 Mar 2026 | Direct |
| Viridian Therapeutics, Inc.\DE | Chief Financial Officer | Stock Option (Right to Buy) | 102,850 | 02 Mar 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | 03 Mar 2026 | 1 | $0 | 4/A | Chief Financial Officer | 09 Mar 2026, 19:49 |
| VRDN | Viridian Therapeutics, Inc.\DE | 02 Mar 2026 | 5 | $0 | 4 | Chief Financial Officer | 04 Mar 2026, 19:15 |
| VRDN | Viridian Therapeutics, Inc.\DE | 03 Mar 2025 | 0 | $0 | 4/A | Chief Financial Officer | 04 Mar 2026, 19:13 |
| VRDN | Viridian Therapeutics, Inc.\DE | 10 Nov 2023 | 1 | $0 | 4 | Senior Vice President of Finance | 13 Nov 2023, 17:17 |
| VRDN | Viridian Therapeutics, Inc.\DE | 12 Sep 2023 | 0 | $0 | 3 | Exhibit 24 - Power of Attorney Senior Vice President of Finance | 19 Sep 2023, 16:30 |